Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.41 |
| ▸ | TUBB | P07437 | 6/20 | 0.41 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.41 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.41 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.41 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.41 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.41 |
| ▸ | TUBB2A | Q13885 | 6/20 | 0.41 |
| ▸ | TUBB8 | Q3ZCM7 | 6/20 | 0.41 |
| ▸ | TUBA3E | Q6PEY2 | 6/20 | 0.41 |
| ▸ | TUBA1A | Q71U36 | 6/20 | 0.41 |
| ▸ | TUBA1C | Q9BQE3 | 6/20 | 0.41 |
| ▸ | TUBB6 | Q9BUF5 | 6/20 | 0.41 |
| ▸ | TUBB2B | Q9BVA1 | 6/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 6/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1399259 | 0.89 | IDO1 (0.48) | IDO1HTR2AHTR6TUBB4ATUBB | |
| SCHEMBL1399205 | 0.87 | AR (0.47) | IDO1HTR2AARSLC6A4IFNAR1 | |
| SCHEMBL1399271 | 0.87 | IFNAR1 (0.54) | IDO1HTR2AHTR6TUBB4ATUBB | |
| SCHEMBL1399276 | 0.86 | PCSK9 (0.46) | IDO1HTR2ASLC6A4DYRK1AIFNAR1 | |
| SCHEMBL1399420 | 0.85 | HTR2A (0.63) | IDO1HTR2AHTR6TUBB4ATUBB | |
| SCHEMBL3182584 | 0.83 | IDO1 (0.55) | IDO1HTR2ATUBB4ATUBBTUBA3C | |
| SCHEMBL1399188 | 0.83 | IDO1 (0.49) | IDO1HTR2AHTR6TUBB4ATUBB | |
| SCHEMBL1399179 | 0.82 | IDO1 (0.48) | IDO1HTR2AHTR6TUBB4ATUBB | |
| SCHEMBL3183849 | 0.79 | IDO1 (0.47) | IDO1HTR2AHTR6TUBB4ATUBB | |
| SCHEMBL1399264 | 0.79 | IDO1 (0.56) | IDO1HTR2ATUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1860100-B1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | LUNDBECK & CO AS H (DK) | 2011-03-02 | — | — | EP | claimed |
| US-7737170-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | claimed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | claimed |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | claimed |
| EP-1860100-A2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. Lundbeck A/S (DK) | 2007-11-28 | — | — | EP | claimed |
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1860100-B1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | LUNDBECK & CO AS H (DK) | 2011-03-02 | — | — | EP | disclosed |
| US-7737170-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7737171-B2 | Uses of 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIS | H. LUNDBECK A/S (DK) | 2010-06-15 | — | — | US | disclosed |
| US-7652150-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRIs | H. LUNDBECK A/S (DK) | 2010-01-26 | — | — | US | disclosed |
| US-7563908-B2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2009-07-21 | — | — | US | disclosed |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-09-04 | — | — | US | disclosed |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | H. LUNDBECK A/S (DK) | 2008-07-24 | — | — | US | disclosed |
| EP-1860100-A2 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. Lundbeck A/S (DK) | 2007-11-28 | — | — | EP | disclosed |
| EP-1701940-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H.Lundbeck A/S (DK) | 2006-09-20 | — | — | EP | disclosed |
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | H. LUNDBECK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| WO-2005061455-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | H. LUNDBECK A/S (DK) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160880-A1 | 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI | TPH1, TPH2, HTR2B | IDO1 31/4885HTR2A 8/4885HTR6 19/4885 |
| US-20080176922-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | IDO1 38/4885HTR2A 8/4885HTR6 18/4885 |
| US-20080214645-A1 | USES OF 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRIS | TPH2, TPH1, HTR1B | IDO1 38/4885HTR2A 8/4885HTR6 18/4885 |
| US-20080214644-A1 | 2-(1H-INDOLYLSULFANYL)-BENZYL AMINE DERIVATIVES AS SSRI | TPH2, TPH1, HTR2B | IDO1 49/4885HTR2A 6/4885HTR6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.